Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 2/2014

Open Access 01-04-2014 | Research article

Angiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patients

Authors: Jeannine Günther, Angela Kill, Mike Oliver Becker, Harald Heidecke, Judith Rademacher, Elise Siegert, Mislav Radić, Gerd-Rüdiger Burmester, Duska Dragun, Gabriela Riemekasten

Published in: Arthritis Research & Therapy | Issue 2/2014

Login to get access

Abstract

Introduction

Agonistic autoantibodies (Aabs) against the angiotensin II receptor type 1 (AT1R) and the endothelin receptor type A (ETAR) have been identified in patients with systemic sclerosis (SSc). In our present study, we examined the expression of the AT1R and the ETAR in human immune cells and the pathological effects mediated through these receptors by their corresponding Aabs.

Methods

Protein expression of AT1R and ETAR on peripheral blood mononuclear cells (PBMCs) from healthy individuals and SSc patients was analyzed using flow cytometry, and mRNA expression of both receptors in PBMCs from healthy donors was examined by real-time PCR. In addition, PBMCs from healthy donors were stimulated in vitro with affinity-purified immunoglobulin G (IgG) fractions from SSc patients positive for AT1R and ETAR Aabs, as well as with IgG from healthy donors serving as controls. Alterations in cell surface marker expression, cytokine secretion and chemotactic motility were analyzed using flow cytometry, enzyme-linked immunosorbent assays and chemotaxis assays, respectively. The results were correlated with the characteristics and clinical findings of the IgG donors.

Results

Both AT1R and ETAR were expressed on PBMCs in humans. Protein expression of both receptors was decreased in SSc patients compared with that of healthy donors and declined during the course of disease. IgG fractions of SSc patients positive for AT1R and ETAR Aabs induced T-cell migration in an Aab level–dependent manner. Moreover, IgG of SSc patients stimulated PBMCs to produce more interleukin 8 (IL-8) and chemokine (C-C motif) ligand 18 (CCL18) than did the IgG of healthy donors. All effects were significantly reduced by selective AT1R and ETAR antagonists. Statistical analysis revealed an association of SSc-IgG induced high IL-8 concentrations with an early disease stage and of high CCL18 concentrations with lung fibrosis onset and vascular complications in the respective IgG donors.

Conclusion

In our present study, we could demonstrate the expression of both AT1R and ETAR on human peripheral T cells, B cells and monocytes. The decreased receptor expression in SSc patients, the inflammatory and profibrotic effects upon Aab stimulation of PBMCs in vitro and the associations with clinical findings suggest a role for Aab-induced activation of immune cells mediated by the AT1R and the ETAR in the pathogenesis or even the onset of the disease.
Appendix
Available only for authorised users
Literature
1.
Sakkas LI, Chikanza IC, Platsoucas CD: Mechanisms of disease: the role of immune cells in the pathogenesis of systemic sclerosis. Nat Clin Pract Rheumatol. 2006, 2: 679-685.CrossRefPubMed
2.
Riemekasten G, Philippe A, Näther M, Slowinski T, Müller DN, Heidecke H, Matucci-Cerinic M, Czirják L, Lukitsch I, Becker M, Kill A, van Laar JM, Catar R, Luft FC, Burmester GR, Hegner B, Dragun D: Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis. 2011, 70: 530-536. 10.1136/ard.2010.135772.CrossRefPubMed
3.
Sakkas LI, Platsoucas CD: Is systemic sclerosis an antigen-driven T cell disease?. Arthritis Rheum. 2004, 50: 1721-1733. 10.1002/art.20315.CrossRefPubMed
4.
Abraham DJ, Varga J: Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol. 2005, 26: 587-595. 10.1016/j.it.2005.09.004.CrossRefPubMed
5.
Prescott RJ, Freemont AJ, Jones CJ, Hoyland J, Fielding P: Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol. 1992, 166: 255-263. 10.1002/path.1711660307.CrossRefPubMed
6.
Trojanowska M: Cellular and molecular aspects of vascular dysfunction in systemic sclerosis. Nat Rev Rheumatol. 2010, 6: 453-460. 10.1038/nrrheum.2010.102.CrossRefPubMed
7.
Nataraj C, Oliverio MI, Mannon RB, Mannon PJ, Audoly LP, Amuchastegui CS, Ruiz P, Smithies O, Coffman TM: Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway. J Clin Invest. 1999, 104: 1693-1701. 10.1172/JCI7451.PubMedCentralCrossRefPubMed
8.
Jurewicz M, McDermott DH, Sechler JM, Tinckam K, Takakura A, Carpenter CB, Milford E, Abdi R: Human T and natural killer cells possess a functional renin-angiotensin system: further mechanisms of angiotensin II-induced inflammation. J Am Soc Nephrol. 2007, 18: 1093-1102. 10.1681/ASN.2006070707.CrossRefPubMed
9.
Marchesi C, Paradis P, Schiffrin EL: Role of the renin-angiotensin system in vascular inflammation. Trends Pharmacol Sci. 2008, 29: 367-374. 10.1016/j.tips.2008.05.003.CrossRefPubMed
10.
Brassard P, Amiri F, Schiffrin EL: Combined angiotensin II type 1 and type 2 receptor blockade on vascular remodeling and matrix metalloproteinases in resistance arteries. Hypertension. 2005, 46: 598-606. 10.1161/01.HYP.0000176744.15592.7d.CrossRefPubMed
11.
Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Egido J: Inflammation and angiotensin II. Int J Biochem Cell Biol. 2003, 35: 881-900. 10.1016/S1357-2725(02)00271-6.CrossRefPubMed
12.
Frommer KW, Müller-Ladner U: Expression and function of ETA and ETB receptors in SSc. Rheumatology (Oxford). 2008, 47: v27-v28. 10.1093/rheumatology/ken274.CrossRef
13.
Schiffrin EL: Vascular endothelin in hypertension. Vascul Pharmacol. 2005, 43: 19-29. 10.1016/j.vph.2005.03.004.CrossRefPubMed
14.
Bellisai F, Morozzi G, Scaccia F, Chellini F, Simpatico A, Pecetti G, Galeazzi M: Evaluation of the effect of bosentan treatment on proinflammatory cytokine serum levels in patients affected by systemic sclerosis. Int J Immunopathol Pharmacol. 2011, 24: 261-264.PubMed
15.
Kawaguchi Y, Takagi K, Hara M, Fukasawa C, Sugiura T, Nishimagi E, Harigai M, Kamatani N: Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors. Arthritis Rheum. 2004, 50: 216-226. 10.1002/art.11364.CrossRefPubMed
16.
Rasini E, Cosentino M, Marino F, Legnaro M, Ferrari M, Guasti L, Venco A, Lecchini S: Angiotensin II type 1 receptor expression on human leukocyte subsets: a flow cytometric and RT-PCR study. Regul Pept. 2006, 134: 69-74. 10.1016/j.regpep.2006.01.007.CrossRefPubMed
17.
Hoch NE, Guzik TJ, Chen W, Deans T, Maalouf SA, Gratze P, Weyand C, Harrison DG: Regulation of T-cell function by endogenously produced angiotensin II. Am J Physiol Regul Integr Comp Physiol. 2009, 296: R208-R216.PubMedCentralCrossRefPubMed
18.
Kintscher U, Wakino S, Kim S, Fleck E, Hsueh WA, Law RE: Angiotensin II induces migration and Pyk2/paxillin phosphorylation of human monocytes. Hypertension. 2001, 37: 587-593. 10.1161/01.HYP.37.2.587.CrossRefPubMed
19.
Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980, 23: 581-590. 10.1002/art.1780230510.CrossRef
20.
LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, Rowell N, Wollheim F: Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988, 15: 202-205.PubMed
21.
Walker UA, Tyndall A, Czirják L, Denton C, Farge-Bancel D, Kowal-Bielecka O, Müller-Ladner U, Bocelli-Tyndall C, Matucci-Cerinic M: Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis. 2007, 66: 754-763. 10.1136/ard.2006.062901.PubMedCentralCrossRefPubMed
22.
23.
Herrera M, Sparks MA, Alfonso-Pecchio AR, Harrison-Bernard LM, Coffman TM: Lack of specificity of commercial antibodies leads to misidentification of angiotensin type 1 receptor protein. Hypertension. 2013, 61: 253-258. 10.1161/HYPERTENSIONAHA.112.203679.PubMedCentralCrossRefPubMed
24.
Abraham DJ, Vancheeswaran R, Dashwood MR, Rajkumar VS, Pantelides P, Xu SW, du Bois RM, Black CM: Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am J Pathol. 1997, 151: 831-841.PubMedCentralPubMed
25.
Nickenig G: Central role of the AT1-receptor in atherosclerosis. J Hum Hypertens. 2002, 16: S26-S33.CrossRefPubMed
26.
Trojanowska M, Varga J: Molecular pathways as novel therapeutic targets in systemic sclerosis. Curr Opin Rheumatol. 2007, 19: 568-573. 10.1097/BOR.0b013e3282e6f495.CrossRefPubMed
27.
Ouali R, Berthelon MC, Bégeot M, Saez JM: Angiotensin II receptor subtypes AT1 and AT2 are down-regulated by angiotensin II through AT1 receptor by different mechanisms. Endocrinology. 1997, 138: 725-733.PubMed
28.
Mayes MD: Endothelin and endothelin receptor antagonists in systemic rheumatic disease. Arthritis Rheum. 2003, 48: 1190-1199. 10.1002/art.10895.CrossRefPubMed
29.
Williams JT, Ingram SL, Henderson G, Chavkin C, von Zastrow M, Schulz S, Koch T, Evans CJ, Christie MJ: Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. Pharmacol Rev. 2013, 65: 223-254. 10.1124/pr.112.005942.PubMedCentralCrossRefPubMed
30.
Rajagopal S, Rajagopal K, Lefkowitz RJ: Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat Rev Drug Discov. 2010, 9: 373-386. 10.1038/nrd3024.PubMedCentralCrossRefPubMed
31.
Dimitrijevic I, Rissler P, Luts L, Edvinsson L: Reduced expression of angiotensin II and angiotensin receptor type 1 and type 2 in resistance arteries from nasal lesions in granulomatosis with polyangiitis (Wegener’s granulomatosis). Scand J Rheumatol. 2011, 40: 448-452. 10.3109/03009742.2011.593545.CrossRefPubMed
32.
Silva-Filho JL, Souza MC, Henriques M, Morrot A, Savino W, Nunes MP, Caruso-Neves C, Pinheiro AA: AT1 receptor-mediated angiotensin II activation and chemotaxis of T lymphocytes. Mol Immunol. 2011, 48: 1835-1843. 10.1016/j.molimm.2011.05.008.CrossRefPubMed
33.
Xu SW, Denton CP, Dashwood MR, Abraham DJ, Black CM: Endothelin-1 regulation of intercellular adhesion molecule-1 expression in normal and sclerodermal fibroblasts. J Cardiovasc Pharmacol. 1998, 31: S545-S547.CrossRefPubMed
34.
Dragun D, Müller DN, Bräsen JH, Fritsche L, Nieminen-Kelhä M, Dechend R, Kintscher U, Rudolph B, Hoebeke J, Eckert D, Mazak I, Plehm R, Schönemann C, Unger T, Budde K, Neumayer HH, Luft FC, Wallukat G: Angiotensin II type 1–receptor activating antibodies in renal-allograft rejection. N Engl J Med. 2005, 352: 558-569. 10.1056/NEJMoa035717.CrossRefPubMed
35.
Okruhlicova L, Morwinski R, Schulze W, Bartel S, Weismann P, Tribulova N, Wallukat G: Autoantibodies against G-protein-coupled receptors modulate heart mast cells. Cell Mol Immunol. 2007, 4: 127-133.PubMed
36.
Wallukat G, Homuth V, Fischer T, Lindschau C, Horstkamp B, Jüpner A, Baur E, Nissen E, Vetter K, Neichel D, Dudenhausen JW, Haller H, Luft FC: Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest. 1999, 103: 945-952. 10.1172/JCI4106.PubMedCentralCrossRefPubMed
37.
Xia Y, Wen H, Bobst S, Day MC, Kellems RE: Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human trophoblast cells. J Soc Gynecol Investig. 2003, 10: 82-93. 10.1016/S1071-5576(02)00259-9.CrossRefPubMed
38.
Zhou CC, Ahmad S, Mi T, Abbasi S, Xia L, Day MC, Ramin SM, Ahmed A, Kellems RE, Xia Y: Autoantibody from women with preeclampsia induces soluble Fms-like tyrosine kinase-1 production via angiotensin type 1 receptor and calcineurin/nuclear factor of activated T-cells signaling. Hypertension. 2008, 51: 1010-1019. 10.1161/HYPERTENSIONAHA.107.097790.PubMedCentralCrossRefPubMed
39.
40.
Dechend R, Gratze P, Wallukat G, Shagdarsuren E, Plehm R, Bräsen JH, Fiebeler A, Schneider W, Caluwaerts S, Vercruysse L, Pijnenborg R, Luft FC, Müller DN: Agonistic autoantibodies to the AT1 receptor in a transgenic rat model of preeclampsia. Hypertension. 2005, 45: 742-746. 10.1161/01.HYP.0000154785.50570.63.CrossRefPubMed
41.
Dechend R, Homuth V, Wallukat G, Kreuzer J, Park JK, Theuer J, Juepner A, Gulba DC, Mackman N, Haller H, Luft FC:AT(1)receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor.Circulation. 2000, 101: 2382-2387. 10.1161/01.CIR.101.20.2382.CrossRefPubMed
42.
Dechend R, Viedt C, Müller DN, Ugele B, Brandes RP, Wallukat G, Park JK, Janke J, Barta P, Theuer J, Fiebeler A, Homuth V, Dietz R, Haller H, Kreuzer J, Luft FC: AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase. Circulation. 2003, 107: 1632-1639. 10.1161/01.CIR.0000058200.90059.B1.CrossRefPubMed
43.
Bobst SM, Day MC, Gilstrap LC, Xia Y, Kellems RE: Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human mesangial cells and induce interleukin-6 and plasminogen activator inhibitor-1 secretion. Am J Hypertens. 2005, 18: 330-336. 10.1016/j.amjhyper.2004.10.002.CrossRefPubMed
44.
Walther T, Wallukat G, Jank A, Bartel S, Schultheiss HP, Faber R, Stepan H: Angiotensin II type 1 receptor agonistic antibodies reflect fundamental alterations in the uteroplacental vasculature. Hypertension. 2005, 46: 1275-1279. 10.1161/01.HYP.0000190040.66563.04.CrossRefPubMed
45.
Hiemann NE, Meyer R, Wellnhofer E, Schoenemann C, Heidecke H, Lachmann N, Hetzer R, Dragun D: Non-HLA antibodies targeting vascular receptors enhance alloimmune response and microvasculopathy after heart transplantation. Transplantation. 2012, 94: 919-924.CrossRefPubMed
46.
Mateo T, Abu Nabah YN, Abu Taha M, Mata M, Cerdá-Nicolás M, Proudfoot AEI, Stahl RAK, Issekutz AC, Cortijo J, Morcillo EJ, Jose PJ, Sanz MJ: Angiotensin II-induced mononuclear leukocyte interactions with arteriolar and venular endothelium are mediated by the release of different CC chemokines. J Immunol. 2006, 176: 5577-5586. 10.4049/jimmunol.176.9.5577.CrossRefPubMed
47.
Savoia C, Schiffrin EL: Inflammation in hypertension. Curr Opin Nephrol Hypertens. 2006, 15: 152-158.PubMed
48.
Brasier AR, Jamaluddin M, Han Y, Patterson C, Runge MS: Angiotensin II induces gene transcription through cell-type-dependent effects on the nuclear factor-κB (NF-κB) transcription factor. Mol Cell Biochem. 2000, 212: 155-169. 10.1023/A:1007133710837.CrossRefPubMed
49.
Nabah YN, Mateo T, Estellés R, Mata M, Zagorski J, Sarau H, Cortijo J, Morcillo EJ, Jose PJ, Sanz MJ: Angiotensin II induces neutrophil accumulation in vivo through generation and release of CXC chemokines. Circulation. 2004, 110: 3581-3586. 10.1161/01.CIR.0000148824.93600.F3.CrossRefPubMed
50.
Schmidt-Ott KM, Kagiyama S, Phillips MI: The multiple actions of angiotensin II in atherosclerosis. Regul Pept. 2000, 93: 65-77. 10.1016/S0167-0115(00)00178-6.CrossRefPubMed
51.
Muller DN, Mervaala EM, Schmidt F, Park JK, Dechend R, Genersch E, Breu V, Löffler BM, Ganten D, Schneider W, Haller H, Luft FC: Effect of bosentan on NF-κB, inflammation, and tissue factor in angiotensin II-induced end-organ damage. Hypertension. 2000, 36: 282-290. 10.1161/01.HYP.36.2.282.CrossRefPubMed
52.
53.
De Palma R, D’Aiuto E, Vettori S, Cuoppolo P, Abbate G, Valentini G: Peripheral T cells from patients with early systemic sclerosis kill autologous fibroblasts in co-culture: Is T-cell response aimed to play a protective role?. Rheumatology (Oxford). 2010, 49: 1257-1266. 10.1093/rheumatology/keq094.CrossRef
54.
Prasse A, Pechkovsky DV, Toews GB, Schäfer M, Eggeling S, Ludwig C, Germann M, Kollert F, Zissel G, Müller-Quernheim J: CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis. Arthritis Rheum. 2007, 56: 1685-1693. 10.1002/art.22559.CrossRefPubMed
55.
Schutyser E, Richmond A, Van Damme J: Involvement of CC chemokine ligand 18 (CCL18) in normal and pathological processes. J Leukoc Biol. 2005, 78: 14-26. 10.1189/jlb.1204712.PubMedCentralCrossRefPubMed
56.
Mathai SK, Gulati M, Peng X, Russell TR, Shaw AC, Rubinowitz AN, Murray LA, Siner JM, Antin-Ozerkis DE, Montgomery RR, Reilkoff RA, Bucala RJ, Herzog EL: Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype. Lab Invest. 2010, 90: 812-823. 10.1038/labinvest.2010.73.PubMedCentralCrossRefPubMed
57.
Prasse A, Pechkovsky DV, Toews GB, Jungraithmayr W, Kollert F, Goldmann T, Vollmer E, Müller-Quernheim J, Zissel G: A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. Am J Respir Crit Care Med. 2006, 173: 781-792. 10.1164/rccm.200509-1518OC.CrossRefPubMed
58.
Luzina IG, Tsymbalyuk N, Choi J, Hasday JD, Atamas SP: CCL18-stimulated upregulation of collagen production in lung fibroblasts requires Sp1 signaling and basal Smad3 activity. J Cell Physiol. 2006, 206: 221-228. 10.1002/jcp.20452.CrossRefPubMed
59.
Rodríguez-Vita J, Sánchez-López E, Esteban V, Rupérez M, Egido J, Ruiz-Ortega M: Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-β-independent mechanism. Circulation. 2005, 111: 2509-2517. 10.1161/01.CIR.0000165133.84978.E2.CrossRefPubMed
60.
Wang W, Huang XR, Canlas E, Oka K, Truong LD, Deng C, Bhowmick NA, Ju W, Bottinger EP, Lan HY: Essential role of Smad3 in angiotensin II-induced vascular fibrosis. Circ Res. 2006, 98: 1032-1039. 10.1161/01.RES.0000218782.52610.dc.PubMedCentralCrossRefPubMed
61.
Koch AE, Kronfeld-Harrington LB, Szekanecz Z, Cho MM, Haines GK, Harlow LA, Strieter RM, Kunkel SL, Massa MC, Barr WG, Jimenez SA: In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis: their role in early and late disease. Pathobiology. 1993, 61: 239-246. 10.1159/000163802.CrossRefPubMed
62.
Suwannalai P, van de Stadt LA, Radner H, Steiner G, El-Gabalawy HS, Zijde CM, van Tol MJ, van Schaardenburg D, Huizinga TW, Toes RE, Rouw LA: Avidity maturation of anti-citrullinated protein antibodies in rheumatoid arthritis. Arthritis Rheum. 2012, 64: 1323-1328. 10.1002/art.33489.CrossRefPubMed
63.
Schmidt K, Martinez-Gamboa L, Meier S, Witt C, Meisel C, Hanitsch LG, Becker MO, Huscher D, Burmester GR, Riemekasten G: Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients. Arthritis Res Ther. 2009, 11: R111-10.1186/ar2766.PubMedCentralCrossRefPubMed
64.
Kodera M, Hasegawa M, Komura K, Yanaba K, Takehara K, Sato S: Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis. Arthritis Rheum. 2005, 52: 2889-2896. 10.1002/art.21257.CrossRefPubMed
65.
Prasse A, Müller-Quernheim J: Non-invasive biomarkers in pulmonary fibrosis. Respirology. 2009, 14: 788-795. 10.1111/j.1440-1843.2009.01600.x.CrossRefPubMed
Metadata
Title
Angiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patients
Authors
Jeannine Günther
Angela Kill
Mike Oliver Becker
Harald Heidecke
Judith Rademacher
Elise Siegert
Mislav Radić
Gerd-Rüdiger Burmester
Duska Dragun
Gabriela Riemekasten
Publication date
01-04-2014
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 2/2014
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar4503

Other articles of this Issue 2/2014

Arthritis Research & Therapy 2/2014 Go to the issue

Research article

Serum C-X-C motif chemokine 13 is elevated in early and established rheumatoid arthritis and correlates with rheumatoid factor levels

Research article

Inhibitor of DNA binding 1 as a secreted angiogenic transcription factor in rheumatoid arthritis

Research article

Increased expression of Mer tyrosine kinase in circulating dendritic cells and monocytes of lupus patients: correlations with plasma interferon activity and steroid therapy

Review

Molecular imaging of rheumatoid arthritis: emerging markers, tools, and techniques

Research article

Chronic oral or intraarticular administration of docosahexaenoic acid reduces nociception and knee edema and improves functional outcomes in a mouse model of Complete Freund’s Adjuvant–induced knee arthritis

Research article

Genetic variant in IL33 is associated with susceptibility to rheumatoid arthritis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits